TSE:4523Pharmaceuticals
Eisai (TSE:4523) Is Down 5.9% After Leqembi Subcutaneous Priority Review News - Has The Bull Case Changed?
In late January 2026, BioArctic’s partner Eisai reported regulatory progress for Leqembi (lecanemab), including an EMA filing for less frequent IV maintenance dosing and a US FDA Priority Review for a weekly subcutaneous autoinjector starting regimen in early Alzheimer’s disease.
This shift toward at-home, less resource-intensive administration could materially influence how Leqembi is used across the treatment journey, potentially reshaping Eisai’s Alzheimer’s franchise profile.
We will now...